JPMorgan invests in fixed-income data startup

By Anna Irrera

(Reuters) - JPMorgan Chase & Co has made a strategic investment in Mosaic Smart Data, a company that has developed technology to help banks make their fixed-income sales and trading businesses more profitable.

The bank, whose fixed-income revenue slumped last year, has taken a minority stake in the London-based startup, the companies said in London on Wednesday.

The financial terms of the deal were not disclosed.

Mosaic will use the funding to double its headcount and expand its platform to cover additional asset classes for new and existing clients, according to a person familiar with the deal.

The investment comes after JPMorgan revealed in October that it had signed a multiyear deal to use Mosaic's technology globally.

Mosaic sells technology that collects and analyzes data from the fixed-income trading divisions of banks to help them make more informed decisions and secure more deals.

The platform helps visualize data and can be used traders to figure out which clients are more likely to be interested in a given deal. It can also be used by bank bosses to determine which trading desk or trader has been performing better.

The investment comes as financial institutions look to adopt more technology that can help them take advantage of the vast amounts of data they store.

Banks have also been looking for ways to deal with a liquidity crunch in fixed-income markets. Tougher post-financial crisis capital requirements have made it more expensive for them to act as market makers in some fixed-income assets, leading their fixed-income divisions to slump.

(Reporting by Anna Irrera; Editing by Jonathan Oatis)

Must Read

Home Depot rides housing boom to record sales, profit

Aug 16, 2016

Home Depot posted record sales and earnings during its second quarter and raised its profit expectations for the year as housing market continues to warm up

Patent for J&J's Remicade invalidated, cheaper version looms

Aug 17, 2016

A cheaper version of Johnson & Johnson's top-selling drug, the rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled a key patent on the drug invalid

Paralympics get a taxpayer bailout in cash-strapped Rio

Aug 18, 2016

Judge rules Rio Games organizers can take public money to put on upcoming Paralympics

Search

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales[at]obserworld.com